Pemetrexed
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00642 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | malignant peritoneal mesothelioma | KG + DL |
| 2 | pleural adenomatoid tumor | KG + DL |
| 3 | pleural mesothelioma | KG + DL |
| 4 | pleural epithelioid mesothelioma | KG + DL |
| 5 | pleural sarcomatoid mesothelioma | KG + DL |
| 6 | pleural biphasic mesothelioma | KG + DL |
| 7 | pericardium cancer | KG + DL |
| 8 | well differentiated papillary mesothelioma | KG + DL |
| 9 | lymphohistiocytoid mesothelioma | KG + DL |
| 10 | iminoglycinuria | KG + DL |
| 11 | male infertility with teratozoospermia due to single gene mutation | KG + DL |
| 12 | rhabdomyosarcoma (disease) | KG + DL |
| 13 | botryoid-type embryonal rhabdomyosarcoma of the vagina | KG + DL |
| 14 | extrahepatic bile duct rhabdomyosarcoma | KG + DL |
| 15 | embryonal extrahepatic bile duct rhabdomyosarcoma | KG + DL |
| 16 | parameningeal embryonal rhabdomyosarcoma | KG + DL |
| 17 | prostate embryonal rhabdomyosarcoma | KG + DL |
| 18 | liver sarcoma | KG + DL |
| 19 | liposarcoma | KG + DL |
| 20 | ovarian myxoid liposarcoma | KG + DL |
| 21 | malignant epithelioid mesothelioma | KG + DL |
| 22 | mesothelioma | KG + DL |
| 23 | sarcomatoid mesothelioma | KG + DL |
| 24 | benign mesothelioma | KG + DL |
| 25 | dermatofibrosarcoma protuberans | KG + DL |
| 26 | small cell lung carcinoma | KG + DL |
| 27 | skeletal muscle neoplasm | KG + DL |
| 28 | malignant visceral pleura tumor | KG + DL |
| 29 | pulmonary blastoma | KG + DL |
| 30 | primary pulmonary lymphoma | KG + DL |
| 31 | well-differentiated fetal adenocarcinoma of the lung | KG + DL |
| 32 | cysticercosis | KG + DL |
| 33 | mixed endometrial stromal and smooth muscle tumor | KG + DL |
| 34 | uterine corpus sarcoma | KG + DL |
| 35 | pancreatic adenocarcinoma | KG + DL |
| 36 | solid pseudopapillary carcinoma of pancreas | KG + DL |
| 37 | osteoclastic giant cell tumor of pancreas | KG + DL |
| 38 | pancreatic carcinoma with mixed differentiation | KG + DL |
| 39 | pancreatic intraductal papillary-mucinous carcinoma | KG + DL |
| 40 | kidney fibrosarcoma | KG + DL |
| 41 | conventional fibrosarcoma | KG + DL |
| 42 | heart fibrosarcoma | KG + DL |
| 43 | mixed ductal-endocrine carcinoma of pancreas | KG + DL |
| 44 | vulva sarcoma | KG + DL |
| 45 | fibroblastic neoplasm | KG + DL |
| 46 | pancreatic signet ring cell adenocarcinoma | KG + DL |
| 47 | malignant exocrine pancreas neoplasm | KG + DL |
| 48 | pancreatic intraductal papillary-mucinous neoplasm | KG + DL |
| 49 | undifferentiated pancreatic carcinoma | KG + DL |
| 50 | pancreatic acinar cell cystadenocarcinoma | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.